

Table of Contents

- [Dashboard](#) 2
- [Content Customization](#) 3
- [Content Management System \(CMS\) Components](#) 4
- [Common Interface Elements Pages](#) 6
 - [Elements Lists](#) 7
 - [Display Order](#) 8
 - [Code view](#) 10
 - [CMS Sections](#) 11
 - [Custom Content Sections](#) 12
- [Sidebar](#) 14
 - [Pages](#) 16
 - [Products](#) 26
 - [IME Data](#) 32
 - [Clinical Trials](#) 34

- [Scientific Congress Data](#) 37
- [Med Info Letters](#) 40
- [Publications](#) 43
 - [Search Content](#) 44
 - [Browse Content](#) 47
 - [Browse Manuscript Topics](#) 49
 - [Browse Presentation Meetings](#) 50
- [Ref Labs & Testing Document Labels](#) 51
- [Medical Information Requests](#) 53
- [Users](#) 55
 - [Medical Science Directors](#) 56
 - [Users \(Melinta\)](#) 59
 - [Guests](#) 61
- [Media](#) 65

Dashboard

melinta

Home

Welcome Nancy

Home / Dashboard

Dashboard

5
MIRF Count
[See more](#)

38
Link Visits
[More info](#)

40
User Registrations
[More info](#)

118
Approved MI Letter Count
[More info](#)

11
Publications Search
[More info](#)

9
MI Library Search
[More info](#)

Links

Show 10 entries Search:

Date	User	Page	Link
8/9/24 2:39 PM	Nancy Robasco	clinical-trials	destination: https://clinicaltrials.gov/study/NCT04368559
8/9/24 1:30 PM	Nancy Robasco	clinical-trials	destination: https://clinicaltrials.gov/study/NCT04368559
8/9/24 1:29 PM	Nancy Robasco	clinical-trials	destination: https://clinicaltrials.gov/study/NCT02687906
8/9/24 1:25 PM	Nancy Robasco	clinical-trials	destination: https://clinicaltrials.gov/study/NCT04368559
7/31/24 11:32 AM	Nicholas Rufa	search-publications	Cornely-Thompson_Final_RZF_NoPriorAntifungals_POSTER_110424.pdf
7/30/24 11:51 AM	Nancy Robasco	grants-research	Melinta Investigator-Sponsored Research Form.pdf
7/30/24 11:45 AM	Nancy Robasco	grants-research	Melinta Investigator-Sponsored Research Form.pdf
7/29/24 3:56 PM	Nicholas Rufa	reference-labs-and-testing	MIN-LAB-SRD Antimicrobial Susceptibility Testing_Final_21Sep23.pdf
7/29/24 3:56 PM	Nicholas Rufa	reference-labs-and-testing	KIM-LAB-SRD Antimicrobial Susceptibility Testing_FINAL_09Aug23.pdf
7/29/24 3:54 PM	Nicholas Rufa	reference-labs-and-testing	BAX-LAB-SRD Antimicrobial Susceptibility Testing_FINAL_08Aug23.pdf

Showing 1 to 10 of 38 entries Previous 1 2 3 4 Next

Activity Log

Log date: 09/06/2024 [submit](#)

Log Info (Public/Front End)

Show 10 entries Search:

View	Date Created	Template	Query string
No data available in table			

Showing 0 to 0 of 0 entries Previous Next

Log Info (Admin/Back End)

Show 10 entries Search:

Content Customization

- The design and layout are fixed to maintain a consistent look across the site.
 - Changes to the design and layout require developer assistance.
- As an Admin user, you have the flexibility to customize your content in two main ways:
 1. Add a **Fully Coded CFML Page**: You can add an entire page coded in ColdFusion Markup Language (CFML). (ie : <https://melintamedicalaffairs.com/clinical-trials>)
 2. Add **Custom Content Sections**: You can build your content by adding one or more custom content sections, which allows for a more modular approach. (ie: <https://melintamedicalaffairs.com/grants-research>)

Content Management System (CMS) Components

(Admin Dashboard Sidebar)

Pages

- Manage pages on the public website

Products

- Manage what products and product display names, are visible on the public website.
- Add product specific documentation, used in Reference Labs and other site pages.

IME Data

- Manage content shown on the Education Activities page. (CME and Videos).

Clinical Trials Data

- Manage content shown on the Clinical Trials page.

Scientific Congress Data

- Manage content shown in Upcoming Congresses page.

Med Info Letters

- Manage content shown in Medical Information Library Search. (E.g., Titles, Keywords, PDF, Approvals, Expirations for SRDs).

Publications / Search Content

- Manage content shown in Search Publications page.

Publications / Browse Content

- Manage content shown in Browse Publications page.

Content Management System (CMS) Components

Publications / Manuscript Topics

- Manage topics/subheadings of content in the Browse Publications/Manuscripts page.

Publications / Presentation Meetings

- Manage meetings/subheadings of content in the Browse Publications/Presentations page.

Ref Labs & Testing Document Labels

- Manage document download labels in the Reference Labs & Susceptibility Testing page

Medical Information Requests

- This is the data repository for any MIRFs entered on from "Submit an MI Request"
- Data is uploaded to Melinta's SFTP server, where it is picked up by IRMS for Case Entry

Medical Science Director

- Manages which MSDs are shown from Find My MSL section (Sets territories etc.)
- The Users (Melinta) is the source data for who can be shown as an MSL.

Users (Melinta)

- Melinta Medical Affairs employees, or site administrators.

Visitors

- Users who registered on the public site for access to Publications/MIL documents or submitting a MIRF.

Media

- Provides upload functionality for Images, Docs and Videos for use on the website

Common Interface Elements

Component Element Lists

initial screen from the sidebar is a list of component elements

Product ⓘ

Help Button

Add +

Display Order Indicators

Document Indicators

Active/Inactive Buttons

Immediate Effect of Active/Inactive Button

When you click the active/inactive button, the visibility of the element changes instantly.

There is no need to click a save button for this change to take effect; The update is **immediate**.

Active – visible on website Inactive – not visible on website

Edit Buttons

Archive Buttons

When you archive an item, it is no longer visible in the listing.

But it is not permanently removed from the database.

The data is retained and can be recovered, by a Database Admin if needed.

Move Order Up/Down Buttons

Sort Order	Product	Group	Display	Full HTML Name	Compound	Pubhive	PI	AST	RLT	RVV	Active	DB Id	Actions
1	Rezzayo	1	Rezzayo ®	REZZAYO® (rezafungin for injection)	rezafungin	REZ	✓	✓	✓	✓	Active	5	[Edit] [Delete]
2	Vabomere	3	Vabomere ®	VABOMERE® (meropenem and vaborbactam) for injection	meropenem-vaborbactam	MEV	✓	✓	✗	✓	Active	6	[Edit] [Delete]
3	Kimyrsa	2	Kimyrsa ®	KIMYRSA® (oritavancin) for injection	oritavancin	ORI	✓	✓	✗	✗	Active	2	[Edit] [Delete]
4	Orbactiv	2	Orbactiv ®	ORBACTIV® (oritavancin) for injection	oritavancin for injection	ORI	✓	✓	✗	✗	Active	4	[Edit] [Delete]
5	Minocin	5	Minocin ®	MINOCIN® (minocycline) for injection	minocycline for injection	MIN	✓	✓	✗	✓	Active	3	[Edit] [Delete]
6	Baxdela	4	Baxdela ®	BAXDELA® (delafloxacin)	delafloxacin	DLX	✓	✓	✗	✗	Inactive	1	[Edit] [Delete]

Showing 1 to 6 of 6 entries

Display Order

Element Position – Column header

For the Move Order Up/Down Buttons to appear. The elements **must** be sorted by the Sort Order values

Click on the sort order column header to show the order sorted

Home / Products

Add +

The arrows in the column headers show the currently sorted column

Click on SortOrder column header to rearrange the product list

Search:

Sort Order	Product	Group	Display	Full HTML Name	Compound	Pubhive	PI	AST	RLT	RVV	Active	DB	Id	Actions
6	Baxdela	4	Baxdela ®	BAXDELA® (delafloxacin)	delafloxacin	DLX	✓	✓	✗	✗	✗	1	✎ ✖	
3	Kimyrsa	2	Kimyrsa ®	KIMYRSA® (oritavancin) for injection	oritavancin	ORI	✓	✓	✗	✗	✓	2	✎ ✖	
5	Minocin	5	Minocin ®	MINOCIN® (minocycline) for injection	minocycline for injection	MIN	✓	✓	✗	✓	✓	3	✎ ✖	
4	Orbactiv	2	Orbactiv ®	ORBACTIV® (oritavancin) for injection	oritavancin for injection	ORI	✓	✓	✗	✗	✓	4	✎ ✖	
2	Rezzayo	1	Rezzayo ®	REZZAYO® (rezafungin for injection)	rezafungin	REZ	✓	✓	✓	✓	✓	5	✎ ✖	
1	Vabomere	3	Vabomere ®	VABOMERE® (meropenem and vaborbactam) for injection	meropenem-vaborbactam	MEV	✓	✓	✗	✓	✓	6	✎ ✖	

Showing 1 to 6 of 6 entries

Previous 1 Next

Display Order (cont'd)

Element Position – Move up/down

Once the Sort Order header is clicked - the move up/down buttons will show

Product Home / Products

[Add +](#) Search:


Sort Order	Product	Group	Display	Full HTML Name	Compound	Pubhive	PI	AST	RLT	RVV	Active	Id	Actions
1	Rezzayo	1	Rezzayo ®	REZZAYO® (rezafungin for injection)	rezafungin	REZ	✓	✓	✓	✓		5	
2	Vabomere	3	Vabomere ®	VABOMERE® (meropenem and vaborbactam) for injection	meropenem-vaborbactam	MEV	✓	✓	✗	✓		6	
3	Kimyrsa	2	Kimyrsa ®	KIMYRSA® (oritavancin) for injection	oritavancin	ORI	✓	✓	✗	✗		2	
4	Orbactiv	2	Orbactiv ®	ORBACTIV® (oritavancin) for injection	oritavancin for injection	ORI	✓	✓	✗	✗		4	
5	Minocin	5	Minocin ®	MINOCIN® (minocycline) for injection	minocycline for injection	MIN	✓	✓	✗	✓		3	
6	Baxdela	4	Baxdela ®	BAXDELA® (delafloxacin)	delafloxacin	DLX	✓	✓	✗	✗		1	

Showing 1 to 6 of 6 entries Previous **1** Next

[Save New Product Order](#) [Revert Product Order](#)

If an element is moved – the Save/Revert Buttons will show

Edit Content - Code View



The "Code View" button allows you to switch between the visual editing mode and the HTML code view.

Editing Raw HTML:

- When you click the "Code View" button, the editor switches from the visual content editor to a text editor that displays the underlying HTML code.
- This is used to directly modify the HTML to add custom tags, adjust styles, or change the structure that is possible through the visual editor.

How to Use It:

- **Toggle to Code View:** Click on the "Code View" button.
- **Edit the HTML:** Modify the HTML as needed
- **Toggle Back to Visual View:** Click the "Code View" button again to return to the WYSIWYG mode. You must return to WYSIWYG mode to save your changes

A screenshot of the HTML code view in the editor. The title bar says "Page Content". Below that is a "Custom Content Section" header with an "Active" toggle, "Add section" button, and a dropdown menu. Below the header is a "Custom Content" section with an "Active" toggle, "Add row" button, and a "row" button. The main area is a text editor showing HTML code. The code includes a row with a left column and a main column. The main column contains a row with a column containing a link and an image. The code is as follows:

```
<div class="row mt-lg-4 pl-sm-4">
  <!-- LEFT -->
  <div class="col-12 col-lg-6">
    <div class="row mb-4">
      <div class="col-6 col-lg-3">
        <div class="mb-4 w-100">
          <div class="d-none d-lg-
            block homeboxes ratio ratio-1x1" style="background-image:
            url(/assets/images/ps-Research-Grants.png); background-size:
            contain; background-repeat: no-repeat; display: flex; justify-
            content: center; align-items: center;">
          </div>
        </div>
      </div>
    <div class="col-12 col-lg-9">
      <div class="homebox-text">
        <a class="homepage-link-
          jade" href="/grants-research">
          </a><div
            class="row"><a class="homepage-link-jade" href="/grants-research">
              <div
                class="col-2 col-sm-1 d-lg-none">
                  
                </div>
              </a><div
                class="col-10 col-sm-11"><a class="homepage-link-iade"
```

CMS Sections

Sections act like templates, defining where and how content like text, images, and other elements will be arranged.

By using the sections, you can customize content on the site

There are two *pre-designed* sections: **Sub-Hero Callout** and **Center Bordered Box**. The look and location of this content cannot be altered by the CMS. Changes to this will require developer assistance.

There are four optional *custom* sections: **Anchors**, **Menu**, **Text**, **Custom Content**. These sections are flexible and are added and tailored by the CMS


Anchors – elements on a page that link content on the same page

Menu – elements that link to other pages in the site

Text – block of text that can be placed on the page

Custom Content – an HTML code snippet that users can create using the CodeView feature. It allows users to input and design any HTML content they need, providing complete control over the structure and appearance of the content.

These sections in the CMS, offer the ability to personalized and dynamically add to the website



Custom Content Sections

You have four different types of content sections you can use to enhance your page:

1. Text

- Use this to add formatted text content such as paragraphs, headings, lists, and more.
- This is ideal for general content, instructions, or any information you want to present in text format.

2. Menu

- Allows you to add a navigation menu to the page.
- Create links to other pages on your site.
- Menus can be styled and structured using CSS and Styles.

3. Anchors

- Use this to create anchor links that help users navigate to specific sections of a page.

4. Custom Content (HTML Block)

- Provides a blank HTML container where you can add any custom HTML code.
- This is ideal for advanced users who want to add complex custom content HTML elements.
- Use this when you need to include specialized content that is not covered by the standard text, menu, or anchor types.

How to Use These Content Types

1. Select Your Method: Decide whether you want to add a fully coded CFML page or use custom content sections.

2. Choose Content Types: If using custom content sections, choose from the four available types (Text, Menu, Anchors, Custom).


3. Add and Customize: Add the chosen content types to your page and customize them as needed. You can mix and match multiple content types to create a rich and engaging page layout.

4. Saving Custom Content Sections: Each section needs to be saved individually. After adding or editing a content section, click the "Save" button next under that section to save your changes.



Save Often!: To avoid losing any changes, remember to save each section as soon as you finish editing it. By understanding these options, you can make the most of the CMS to create flexible and dynamic pages tailored to your content needs.

Sidebar

Clickable link to site



Click to expand



Pages

- Manage the content and the visibility of pages and elements on the website, toggling between active and inactive status as needed.

Pages List

Pages 1 Home / Pages

[Add +](#) [Regenerate Rewrites ↻](#) [Edit Menus and Sidebar ☰](#)

Current Archived

Show entries Search:

Sub Title	Slug	Preset Sections	Custom Sections or Template	Active	ID	Actions
	/idweek2024		text		36	
Sub title for test page	/test-page	subHero Callout	borderedbox,menu,text,grid		33	
Clinical Trials	/clinical-trials	subHero Callout, center Bordered Box	/views/clinical-trials.cfm		29	
Search Publications	/search-publications-test		/views/search-publications.cfm		28	
Upcoming Scientific Meeting Presence	/upcoming-congresses	subHero Callout	/views/upcoming-congresses.cfm		26	
Medical Information	/medical-information-library	center Bordered Box	/views/medical-information-library.cfm		25	
Reference Labs & Susceptibility Testing	/reference-labs-and-testing	subHero Callout, center Bordered Box	/views/reference-labs-and-testing.cfm		23	
Medical and Research Grants	/grants-research	subHero Callout	menu,anchors,text,text		22	
Contact Us	/contactus-chat		/views/contactus-chat.cfm		16	
Contact Us	/contactus-report		/views/contactus-report.cfm		15	
Contact Us	/contactus-call		/views/contactus-chat.cfm		14	
Medical Inquiry Request From	/medical-inquiry-request		/views/medical-inquiry-request.cfm		12	
	/mma-template		/views/mmaTemplate.cfm		11	
Contact Us	/contact-us	subHero Callout, center Bordered Box	/views/contact-us.cfm		10	
Publications	/search-publications	subHero Callout	/views/publications.cfm		8	
Educational Activities	/educational-activities	subHero Callout	/views/educationalActivities.cfm		7	
	/createAccount		/createAccount.cfm		4	
Login	/login		/views/login.cfm		2	
Melinta Medical Affairs	/home	subHero Callout	customcontent		1	

Showing 1 to 19 of 19 entries Previous 1 Next

Clickable link to webpages

Section Content Indicators

Added Custom Section Indicators

Edit Menus

Modify and reorder website top nav

Using the 'Drag' Icon, drag navigation element up/down to desired position.

Drag Icon

The image illustrates the process of editing website navigation menus. On the left, a 'Menus' configuration panel is shown with a 'Right Sidebar' view. The menu structure includes: Home, Resources (Medical & Research Grants, Educational Activities, Search Publications, Our Products, Reference Labs & Susceptibility Testing, Clinical Trials), Medical Information (Search Medical Information, Submit an MIR, Product Information), and Contact us (Call / Email, Find my MSL, Upcoming Congresses). Each item has a 'Drag' icon (a blue arrow) and other control icons (checkmark, minus, plus, delete). A box labeled 'Drag Icon' has arrows pointing to these icons. On the right, the live website is shown with a dark blue header containing the Melinta Therapeutics logo and navigation links: Home, Resources, Medical Information, Contact us, and Hello Nancy!. Below the header is a large banner with the text 'Welcome to Melinta Medical Affairs' and a description of the site's purpose. A red bar below the banner says 'Thank you for visiting Melinta Medical Affairs online.' At the bottom, there are two main content areas: 'Research, Publication and IME Grants' and 'Educational Resources'. An orange arrow points from the 'Home' item in the menu editor to the 'Home' link in the website header.

Edit Right Sidebar

Modify and reorder sidebar and mobile bottom bar

The image shows a configuration interface for a right sidebar and mobile bottom bar. The interface is divided into two main sections: a configuration area on the left and a preview area on the right.

Configuration Area (Left):

- At the top right, there is a status indicator: "Action is Immediate" with three small icons (green, red, blue).
- Below this, there are two tabs: "Menus" and "Right Sidebar".
- The main heading is "Side Bar".
- Below the heading, there is a button: "Add Right Sidebar Item".
- There are four items listed in a vertical stack, each with a vertical double-headed arrow on the left for reordering and three icons (green, blue, red) on the right for actions (toggle, edit, delete).
 - Item 1: "Call" (id: 11)
 - Item 2: "Email" (id: 12)
 - Item 3: "AE" (id: 13)
 - Item 4: "QR" (id: 14)

Preview Area (Right):

- The preview area shows a mobile view of the sidebar. It has a dark red header bar at the top.
- Below the header, there are four items stacked vertically:
 - A telephone icon.
 - An envelope icon.
 - The text "AE".
 - A QR code.

Annotations:

- An orange arrow points from the "Call" item in the configuration area to the telephone icon in the mobile preview.
- Another orange arrow points from the "Call" item in the configuration area to a mobile bottom bar.

Mobile Bottom Bar (Inset):

- The bottom bar is a dark grey bar at the bottom of the mobile view.
- It contains four items from left to right:
 - A telephone icon.
 - An envelope icon.
 - The text "AE".
 - A QR code.
- Text above the icons reads: "Learn about our grants process, including areas of interest. Download forms to submit an".

Edit Page

Tab 1 Principal Elements

Pages 1 Home / Pages

Principal Elements Custom Sections SEO /grants-research DB id: 22

Title
Melinta Medical Affairs

Sub-title
Medical and Research Grants

Title Sub-heading
Melinta is committed to supporting innovative research initiatives and education programs that advance medical care, and foster an increased understanding of scientific, clinical, and healthcare issues to improve patient outcomes

Slug (in URL)
grants-research

Hero Class
Select a Hero Image 

'Preset' Sections

Sub-Hero Callout
B I U X' X, A T|
Melinta considers Grant requests based on the merits of the request and how the requests align to our research and educational areas of interest

Center Bordered Box
B I U X' X, A T|

Save Cancel

'Preset' Sections - Sub-Hero Callout and Center Bordered Box

Pages 1 Home / Pages

Principal Elements Custom Sections SEO /home
DB id: 1

Title
Welcome to

Sub-title
Melinta Medical Affairs

Title Sub-heading
This online site is intended to provide information and resources to aid Healthcare Providers in making informed, timely, and evidence-based decisions on the use of our therapies for appropriate patients.

Slug (in URL)
home

Hero Class
Select a Hero Image 

'Preset' Sections

Sub-Hero Callout
Thank you for visiting Melinta Medical Affairs online.

Center Bordered Box

melinta
therapeutics

Home Resources Medical Information Contact us Hello Nancy!

Welcome to Melinta Medical Affairs

This online site is intended to provide information and resources to aid Healthcare Providers in making informed, timely, and evidence-based decisions on the use of our therapies for appropriate patients.

Thank you for visiting Melinta Medical Affairs online.

**Research, Publication and IME Grants**
Learn about our grants process, including areas of interest. Download forms to submit an application for support of Investigator Sponsored Research (ISR), Independent Medical Education (IME) programs, and Publications.

**Educational Resources**
Access educational resources to learn about our products and associated disease states, including [medical education programs, publications, clinical trials, and reference lab and susceptibility testing information.](#)

**Medical Information Library**
Find answers to your medical questions about our products by [searching our online library of medical information.](#)

**Connect with Us**
See ways to contact Melinta Medical Affairs. [Submit an inquiry to Medical Information.](#) Find your [Medical Science Liaison.](#) See where to meet us at an [upcoming scientific congress...](#)



AE


'Custom' Section - Anchors

Section Position Number

Order section is display on page

Move Section

Used move the entire section up / down

Collapse/Expand Section

Item Position

Position item is displayed within section

Move within Section

Used to move content up or down with the section

'Custom' Section - Menu

Section Position Number
Order section is display on page

Item Position
Position item is within section

Move Section
Used move the entire section up / down


The screenshot shows a CMS configuration page for a menu. At the top, there are tabs for 'Principal Elements' and 'Custom Sections'. Below this, there are two main sections for configuring menu items. The first section is for a 'Menu Section' and the second is for a 'Menu Item'. Each section has a 'Label' field, an 'HRef' field, a 'CSS Id' field, and a 'CSS Class' field. There are also 'Active', 'Add Item', and 'Item' buttons for each section. At the bottom, there is a 'CSS for Menu Section' field and a 'No changes detected.' message.

Collapse/Expand Section

The screenshot shows the Melinta Medical Affairs website. The header includes the Melinta logo and navigation links: Home, Resources, Medical Information, Contact us, and Hello Nancy!. The main content area features a banner for 'Melinta Medical Affairs Medical and Research Grants' with a description of the company's commitment to supporting research. Below the banner, there is a navigation menu with buttons for Educational Activities, Medical & Research Grants, Publications, Reference Labs & Susceptibility Testing, and Clinical Trials. A section titled 'Investigator Sponsored Research (ISR) Grants' is highlighted, with a sub-section for 'Investigator Initiated Studies'.

'Custom' Section – Custom Content

Use the codeview button to edit the HTML code of the content.



The screenshot shows the 'Page Content' editor interface. The title is 'Custom Content Section'. The editor is active, and the codeview button (represented by a code icon) is highlighted with a red box. The HTML code is as follows:

```
<div class="row mt-lg-4 pl-sm-4">
  <!-- LEFT -->
  <div class="col-12 col-lg-6">

    <div class="row mb-4">
      <div class="col-6 col-lg-3">
        <div class="mb-4 w-100">

          <div class="d-none d-lg-
block homeboxes ratio ratio-1x1" style="background-image:
url(/assets/images/ps-Research-Grants.png); background-size:
contain; background-repeat: no-repeat; display: flex; justify-
content: center; align-items: center;">
            </div>
          </div>
        </div>
      <div class="col-12 col-lg-9">
        <div class="homebox-text">
          <a class="homepage-link-
jade" href="/grants-research">
            </a><div
class="row"><a class="homepage-link-jade" href="/grants-research">
              <div
class="col-2 col-sm-1 d-lg-none">
                
              </div>
            </a><div
class="col-10 col-sm-11"><a class="homenage-link-iaed">
```

Products

Products

- **List of all products** (active and inactive) in the system. List does not include archived products.
- **Edit product information** - Modify labels and other textual content associated with each product.
- **Add new products**
- **Archive products**
- **Manage documents** - Manage documents related to each product, used in Reference Labs and other site pages.
- **Control Product Visibility** - Dynamically toggle whether product and/or product content elements are visible on the site to users.

Column Headers

Sort Order	Display order on the website - Search Publications / Browse AND in Reference Labs and testing.
Product Name	(i.e. Vabomere)
Group	Used to combine products on the website. The name is arbitrary and is used to combine content it does not get used for anything other than grouping content
Display Name	(i.e. Vabomere ®)
Full HTML Name	(i.e. 'VABOMERE® (meropenem and vaborbactam) for injection')
Compound	Generic name (i.e. 'meropenem-vaborbactam')
Pubhive	Abbreviation of product name used by pubhive (i.e. 'MEV')
PI	Indicator if PI Doc is uploaded and available for download or no document available
Reference Lab Document Categories	Indicator if Docs are uploaded and available for download or no document available
Active Buttons	Indicator if product is visible on the website. Clicking on this button will toggle visibility. This action is immediately reflected on the website.
DB Id	Database unique record Id (used by DBAdmin)
Actions Buttons	Edit and Archive buttons

Products List

Product  [Help / Information](#)

[Add +](#) [Group products together](#) [Reference Lab Document](#) [Edit / Archive](#) [Products](#)

Search:

Abbreviation used by pubhive

Sort Order	Product	Pub Docs Group	Display	Full HTML Name	Compound	Pubhive	PI	AST	RLT	RVV	Active	Id	Actions
1 	Rezzayo	REZ	Rezzayo [®]	REZZAYO [®] (rezafungin for injection)	rezafungin for injection	REZ	✓	✓	✓	✓		5	 
2 	Kimyrsa	ORI	Kimyrsa [®]	KIMYRSA [®] (oritavancin) for injection	oritavancin for injection	ORI	✓	✓	×	×		2	 
3 	Vabomere	MEV	Vabomere [®]	VABOMERE [®] (meropenem and vaborbactam) for injection	meropenem-vaborbactam	MEV	✓	✓	×	✓		6	 
4 	Orbactiv	ORI	Orbactiv [®]	ORBACTIV [®] (oritavancin) for injection	oritavancin for injection	ORI	✓	✓	×	×		4	 
5 	Minocin	MIN	Minocin [®]	MINOCIN [®] (minocycline) for injection	minocycline for injection	MIN	✓	✓	×	✓		3	 
6 	Baxdela	DLX	Baxdela [®]	BAXDELA [®] (delafloxacin)	delafloxacin	DLX	✓	✓	×	×		1	 

Showing 1 to 6 of 6 entries

[Previous](#) [1](#) [Next](#)

Sort order Buttons

Active (visible) Button

Product Sort

Manage the order the products appear on website pages

The image shows a product management interface with a table of products and a preview of the website page. The table has columns for Order, Product, Group, Display, Full HTML Name, Compound, and Publication. The products listed are Vabomere, Rezzayo, Kimyrsa, Orbactiv, Minocin, and Baxdela. The 'Order' column is circled in orange, and arrows point from it to the 'Order' column in the table and to the 'REZZAYO' product in the preview. The preview shows a website page with a navigation bar, a text block, and a grid of product cards. The 'REZZAYO' product card is highlighted in yellow. Below the grid is a list of products with 'VIEW' buttons.

Order	Product	Group	Display	Full HTML Name	Compound	Pub
1	Vabomere	3	Vabomere	VABOMERE® (meropenem and vaborbactam) for injection	meropenem-vaborbactam	ME
2	Rezzayo	1	Rezzayo®	REZZAYO® (rezafungin for injection)	rezafungin	REZ
3	Kimyrsa	2	Kimyrsa®	KIMYR		
4	Orbactiv	2	Orbactiv®	ORBAC		
5	Minocin	5	Minocin®	MINOC		
6	Baxdela	4	Baxdela®	BAXDE		

Showing 1 to 6 of 6 entries

REZZAYO VIEW

VABOMERE VIEW

KIMYRSA and ORBACTIV VIEW

MINOCIN VIEW

BAXDELA VIEW

Edit Product

Edit Product Home / Product DB Id: 5

Product Name:

Product Display Name:

Full HTMLName:

PubHive Name:

Group:


is Active: Yes No

Prescribing Information

Link to Brand Page PI:

Reference Lab and Testing Document(s) Edit Ref Labs & Testing Document Labels

Doc Type	Label (appears on site)	Upload	Doc Filename
AST	Antimicrobial Susceptibility Testing (AST)		/Media/InfoDB/REZZAYO/REZ-LAB-SRD%20AST%20Devices_FIN/
RLT	Reference Lab Testing		/uploads/2024/07/REZ-LAB-SRD Reference Laboratory Testing_FINAL_
RVV	Resources for Validation-Verification		/uploads/2024/06/REZ-LAB-SRD%20Resources%20Validation-Verifica



Upload buttons

IME Data

Independent Medical Education

Add +

Show 25 entries

Search:

IME Type	IME Provider	IME Title	IME SubTitle	Position/Order	IME Expires	Expiration Label	Active	Actions
Antimicrobial Resistance Video		Race Against Resistance: The Life And Death Struggle To Save Antibiotics BBC StoryWorks – YouTube ↗		4	12/31/2099	Not Applicable		
Antimicrobial Resistance Video		U.S. Senate Committee on Health, Education Labor & Pension. Subcommittee Hearing. Superbugs: The Impact of Antimicrobial Resistance on Modern Medicine ↗		5	12/31/2099			
Antimicrobial Resistance Video		Antimicrobial Resistance: The End of Modern Medicine? - with Dame Sally Davies ↗		6	12/31/2099			
Enduring Online Activity	MAD-ID, Making a Difference in Infectious Diseases®	Updates and Advancements in Invasive Candidiasis ↗		7	6/15/2024			
Enduring Online Program	IDSA Foundation Dr John G. Bartlett Memorial Educational Series	The Fungal Foe Among Us: Candidemia and Invasive Candidiasis Awareness ↗		1	12/31/2099	Not Applicable		
Interactive, Web-Based CME Activity	Mycoses Study Group Education & Research Consortium and Terranova Medica. FungusCME.org – The MSG-ERC Continuing Education Portal	Case Studies in Optimal Management of Invasive Candidiasis ↗		8	9/11/2024			
Podcast	Society of Infectious Diseases Pharmacists (SIDP) — Breakpoints, the SIDP Podcast	Making the Right Choice Easy: Antimicrobial Stewardship in the Emergency Department (#81) ↗		2	12/31/2099	Not applicable		
Podcast	Clinical Care Options (CCO) in partnership with ProCE, LLC and the Society of Infectious Diseases Pharmacists (SIDP)	Long-Acting Lipoglycopeptides for Skin and Soft Tissue Infections: Implementation Into Practice ↗		3	12/31/2099	Released August 08, 2023		

Showing 1 to 8 of 8 entries

Previous **1** Next

Clinical Trials

Clinical Trials List

Group Position Number

Used to group content together, and it indicates the order the group appears on the page

Header

Only first header in group is show on site

Move Group

Used to move entire group up or down in order

Position within Group

Order content appears within a group on the site

Position	Product	Phase	Header	Study Id	Study Title	clinicaltrials.gov Id	Study Type	Sponsors	Is Active	Actions
Drug Group Position 1 [↑] [↓]										
Position in group ①	REZZAYO	3	Phase 3 Multicenter Adult Double-Blind	CD101.IV.3.08	Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases (IFD) in Adults Undergoing Allogeneic Blood and Marrow Transplant (ABMT)	NCT04368559	Interventional			
Drug Group Position 2 [↑] [↓]										
①	ORBACTIV	1	Phase 1 Pediatric US Open-Label	TMC-ORI-11-01	Phase 1 Pediatric US Open-Label: Dose-finding, Pharmacokinetics (PK), Safety and Tolerability Study in Pediatric Subjects with Suspected or Confirmed Bacterial Infections	NCT05599295	Interventional			
Position in group ②	KIMYRSA, ORBACTIV	1	Phase 1 Pediatric US Open-Label	ML-ORI-201	Randomized, Open-Label, Safety and Tolerability Study in Pediatric Subjects with Acute Bacterial Skin and Skin Structure Infections (ABSSSIs)	NCT02134301	Interventional			
Drug Group Position 3 [↑] [↓]										
Position in group ①	VABOMERE	1	Phase I Pediatric Open-Label	Rempex 507	Dose-finding, PK, Safety, and Tolerability Study of a Single Dose of Meropenem-Vaborbactam in Pediatric Subjects with Serious Bacterial Infections	NCT02687906	Interventional			

Change Group

Move content to a new group. Careful! not to move content to group with different product – results may not be what was intended

Move within Group

Used to move content up or down with the group

[Educational Activities](#)
[Medical & Research Grants](#)
[Publications](#)
[Reference Labs & Susceptibility Testing](#)
[Clinical Trials](#)



Phase 3 Multicenter Adult Double-Blind
Rezafungin (REZZAYO)
 ReSPECT Phase 3 Adult ABMT Study Study ID: CD101.IV.3.08 [1] Study Title: Rezafungin Compared to Standard Antimicrobial Regimen for Prevention Fungal Diseases (IFD) in Adults Undergoing Allogeneic Blood and Marrow Transplant (ABMT)
 ClinicalTrials.gov ID and Link: [NCT04368559](#)

Melinta has licensed US commercial rights to rezafungin from Mundipharma, which is the sponsor of this study.



Phase 1 Pediatric US Open-Label
Oritavancin (KIMYRSA and ORBACTIV)
 Oritavancin 3-hr or 1-hr Infusion Study ID: ML-ORI-201 [2] Study Title: Randomized, Open-Label, Safety and Tolerability Study in Pediatric Subjects with Bacterial Skin and Skin Structure Infections (ABSSSIs)
 ClinicalTrials.gov ID and Link: [NCT02134301](#)

Oritavancin 3-hr infusion Study ID: TMC-ORI-11-01 [3] Study Title: Phase 1 Pediatric US Open-Label: Dose-finding, Pharmacokinetics (PK), Safety and Tolerability Study in Pediatric Subjects with Suspected or Confirmed Bacterial Infections
 ClinicalTrials.gov ID and Link: [NCT05599295](#)

Edit Clinical Trials

Clinical Trials Home / Clinical Trials

DB Id: 3

Product

Select
Baxdela (delafloxacin)
Kimyrsa (oritavancin)
Minocin (minocycline for injection)
Orbactiv (oritavancin for injection)
Rezzayo (rezafungin)
Vabomere (meropenem-vaborbactam)

Header

B I U **S X' X,** **A** **</>** **T1**

Phase 3 Multicenter Adult Double-Blind

Study Label

B I U **S X' X,** **A** **</>** **T1**

ReSPECT Phase 3 Adult ABMT Study

Study ID

B I U **S X' X,** **A** **</>** **T1**

CD101.IV.3.08

Study Title

B I U **S X' X,** **A** **</>** **T1**

Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases (IFD) in Adults Undergoing Allogeneic Blood and Marrow Transplant (ABMT)

Study Type

Interventional

GOV ID

NCT04368559

Phase

3

Disclaimer

B I U **S X' X,** **A** **</>** **T1**

Melinta has licensed US commercial rights to rezafungin from Mundipharma, which is the sponsor of this study.

isActive

Yes No

Save Cancel

Scientific Congress Data

Scientific Congress

[Home](#) / Scientific Congress

Add +

*Gray text indicates meeting has ended

Show 25 entries

Search:

ID	Name Abbrev	Name Full	Start	End	City	State	Country	Active	Actions
1	ESCMID	ESCMID Global	4/27/24	4/30/24	Barcelona		Spain		
2	MAD-ID	Making a Difference In Infectious Diseases®	5/8/24	5/11/24	Orlando	Florida			
3	CLSI	Clinical and Laboratory Standards Institute	6/21/24	6/25/24	Chicago	Illinois			
4	MSGERC	Mycoses Study Group Education & Research Consortium.	9/4/24	9/6/24	Colorado Springs	Colorado			
5	IDWeek	IDWeek	10/16/24	10/20/24	Los Angeles	California			

Showing 1 to 5 of 5 entries

Previous 1 Next

Edit Meeting

DB Id: 1

Abbreviated Name

ESCMID

Full Name

ESCMID Global

Start date

04/27/2024



End date

04/30/2024



City

Barcelona

State

Please Select



OR

Country

Spain



is Active? Yes No

Save

Cancel

Med Info Letters

Medical Information Keyword Search

Add +

Show 25 entries

Search:

Code	Product Name	Title / DOC ID	Key Words	Approved Date	Expiration Date	Status	Active	Actions
AVA	Rezzayo	Availability and Ordering REZ-AVA-SRD Availability and Ordering REZ-AVA-SRD Availability and Ordering_FINAL_04Aug23.pdf	22 KEY WORDS	8/4/2023	8/4/2024	Approved		
CPH	Kimyrsa	Pharmacokinetics KIM-CPH-SRD Pharmacokinetics KIM-CPH-SRD Pharmacokinetics_FINAL_25Oct23.pdf	22 KEY WORDS	10/25/2023	10/25/2024	Approved		
CPH	Kimyrsa	Pharmacokinetic Model Data for Multiple Weekly Infusions KIM-CPH-SRD Pharmacokinetic Data for Multiple Infusions KIM-CPH-SRD Pharmacokinetic Data for Multiple Infusions_FINAL_14May24.pdf	32 KEY WORDS	5/15/2024	5/15/2025	Approved		
DDI	Kimyrsa	Interaction With Direct Oral Anticoagulants KIM-DDI-SRD Interaction with DOACs KIM-DDI-SRD Interaction with DOACs_FINAL_05Oct23.pdf	32 KEY WORDS	10/5/2023	10/5/2024	Approved		
DDI	Kimyrsa	Effect on Coagulation Tests KIM-DDI-SRD Effect on Coagulation Tests KIM-DDI-SRD Effect on Coagulation Tests_FINAL_08May24.pdf	40 KEY WORDS	5/8/2024	5/8/2025	Approved		
DDI	Kimyrsa	Interaction with Warfarin KIM-DDI-SRD Interaction with Warfarin KIM-DDI-SRD Interaction with Warfarin_FINAL_10May24.pdf	17 KEY WORDS	5/10/2024	5/10/2025	Approved		
DDI	Baxdela	Interaction with Warfarin and Coagulation Tests BAX-DDI-SRD Interaction with Warfarin and Coagulation Tests BAX-DDI-SRD Interaction with Warfarin and Coagulation Tests_FINAL_12Mar24.pdf	12 KEY WORDS	3/12/2024	3/12/2025	Approved		
DOS	Vabomere	Compatibility with Drug Reconstitution Systems, Vial Adaptors, Transfer Devices VAB-DOS-SRD Drug Reconstitution Systems_Adaptors VAB-DOS-SRD Drug Reconstitution Systems_Adaptors_FINAL_10Nov23.pdf	14 KEY WORDS	11/10/2023	11/10/2024	Approved		
DOS	Vabomere	Infusion Less Than 3 Hours VAB-DOS-CTM Infusion Less Than 3 Hours VAB-DOS-CTM Infusion Less than 3 Hours_FINAL_09Feb23.pdf	14 KEY WORDS	2/9/2023	2/9/2024	Approved		
DOS	Kimyrsa	Compatibility with Drug Reconstitution Systems, Vial Adaptors, Transfer Devices KIM-DOS-SRD Drug Reconstitution Systems_Adaptors KIM-DOS-SRD Drug Reconstitution Systems_Adaptors_FINAL_25Oct23.pdf	14 KEY WORDS	10/25/2023	10/25/2024	Approved		
DOS	Orbactiv	Preparation and Administration of an 800 mg Dose ORB-DOS-SRD Preparation and Administration of an 800 mg Dose ORB-DOS-SRD Preparation and Administration of an 800 mg Dose_FINAL_21Dec23.pdf	8 KEY WORDS	12/21/2023	12/21/2024	Approved		
DOS	Orbactiv	Multiple Dose Use ORB-DOS-SRD Multiple Dose Use ORB-DOS-SRD Multiple Dose Use_FINAL_14Feb2024.pdf	18 KEY WORDS	2/14/2024	2/14/2025	Approved		
DOS	Baxdela	Compatibility with Drug Reconstitution Systems, Vial Adaptors, Transfer Devices BAX-DOS-SRD Drug Reconstitution Systems_Adaptors BAX-DOS-SRD Drug Reconstitution Systems_Adaptors_FINAL_10Nov23.pdf	14 KEY WORDS	11/13/2023	11/13/2024	Approved		

Edit Page

productid

5

Approved_Date

2023-08-04 00:00:00.0

Author

CTM_Additional_Uses

Code

AVA

DOC_ID

REZ-AVA-SRD Availability and Ordering

Expiration_Date

2024-08-04 00:00:00.0

HCP_Y_or_N

Yes

Key_Words

,availability,available,cost,distribute,distribution,launch,ndc,package,packaging,price,pricing,WAC,wholesale acquisition cost,wholesale,distributors,distributor,wholesaler,wholesalers,order number,order number

Notes

SRD_or_CTM

SRD

Status

Approved

Title

Availability and Ordering

col_1

col_2

1

isActive

Yes No

Save

Cancel

Publications

Publications / Search Content

Add

Search:

Title	DOI	Product	MedlineID	JournalFullName	Category	Active	Actions
1056. Safety and Tolerability of Dalbavancin in Vancomycin Allergic Patients – A Case Series	10.1093/ofid/ofab466.1250.	KIMYRSA® (oritavancin) for injection		Open Forum Infectious Diseases; Open Forum Infect Dis	Manuscript		
2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.	10.1161/CIR.0000000000001106.	KIMYRSA® (oritavancin) for injection	36322642	Circulation	Manuscript		
A 9-Point Risk Assessment for Patients Who Inject Drugs and Require Intravenous Antibiotics: Focusing Inpatient Resources on Patients at Greatest Risk of Ongoing Drug Use.	10.1093/cid/ciy722.	KIMYRSA® (oritavancin) for injection	30165395	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America	Manuscript		
A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms.	10.1128/AAC.00181-13.	BAXDELA® (delafloxacin)	23571532	Antimicrobial agents and chemotherapy	Manuscript		
A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study.	10.1093/cid/ciy165.	BAXDELA® (delafloxacin)	29518178	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America	Manuscript		
A Phase 3 Study to Compare Delafloxacin With Moxifloxacin for the Treatment of Adults With Community-Acquired Bacterial Pneumonia (DEFINE-CABP).	10.1093/ofid/ofz514.	BAXDELA® (delafloxacin)	31988972	Open forum infectious diseases	Manuscript		
A Post-Neurosurgical Infection due to KPC-Producing Klebsiella pneumoniae Treated with Meropenem-Vaborbactam: A Case Report.	10.1016/j.ijid.2022.07.073.	VABOMERE® (meropenem and vaborbactam) for injection	35932967	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases	Manuscript		
A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections.	10.1016/j.ijid.2014.10.009.	BAXDELA® (delafloxacin)	25448332	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases	Manuscript		
A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial	10.1093/cid/ciaa803.	VABOMERE® (meropenem and vaborbactam) for injection	32785589	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America	Manuscript		

Edit

DB id: f

Product

Select one or more
Vabomere (meropenem-vaborbactam)
Rezzayo (rezafungin)
Kimyrsa (oritavancin)
Orbactiv (oritavancin for injection)
Minocin (minocycline for injection)
Baxdela (delafloxacin)

Title

2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committ

Authors

Isselbacher EM;Preventza O;Hamilton Black J;Augoustides JG;Beck AW;Bolen MA;Braverman AC;Bray BE;Brown-Zimmerman MM;Chen EP;Collins TJ;DeAnda A;Fanola CL;

Year

Journal Full Name

Circulation

DOI

10.1161/CIR.0000000000001106.

Publication Category

NULL Manuscript Presentation

Publication Group Label

Publication URL

<https://pubmed.ncbi.nlm.nih.gov/36322642>

MedlineId

36322642

OAArticleLink

<https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000001106>

authorAbstract

B *I* U ~~AB~~                                                    

AIM :The "2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease" provides recommendations to guide clinicians in the diagnosis, genetic evaluation and family screening, medical therapy, endovascular and surgical treatment, and long-term surveillance of patients with aortic disease across its multiple clinical presentation subsets (ie, asymptomatic, stable symptomatic, and acute aortic syndromes).METHODS :A comprehensive literature search was conducted from January 2021 to April 2021, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, CINHL Complete, and other selected databases relevant to this guideline. Additional relevant studies, published through June 2022 during the guideline writing process, were also considered by the writing committee, where appropriate. Structure: Recommendations from previously published AHA/ACC guidelines on thoracic aortic disease, peripheral artery disease, and bicuspid aortic valve disease have been updated with new evidence to guide clinicians. In addition, new recommendations addressing comprehensive care for patients with aortic disease have been developed. There is added emphasis on the role of shared decision making, especially in the management of patients with aortic disease both before and during pregnancy. The is also an increased emphasis on the importance of institutional interventional volume and multidisciplinary aortic team expertise in the care of patients with aortic disease.

citation

B *I* U ~~AB~~                                                    

Publications / Browse Content

There are two types of 'browseable' content: **Manuscripts** and **Presentations**.

- **Manuscripts** are organized into subcategories called **Topics**.
- **Presentations** are organized into subcategories called **Meetings**.

Both the subcategories and the content within them can be edited and reordered as needed.

- Manage content within each subcategory for Manuscripts (topics) and Presentations (meetings).
- Arrange the content order within each subcategory.

Publications Browse Home / Publications Browse

[Add +](#)

VABOMERE REZZAYO KIMYRSA and ORBACTIV MINOCIN BAXDELA

Search:

Position	Title	articleUrl / filepath	Is Active	Id	Actions
Manuscripts					
Registrational and Pivotal Trial Data					
Position in topic ①	Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.	https://jamanetwork.com/journals/jama/fullarticle/2673552		48	
Position in topic ②	Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.	https://link.springer.com/article/10.1007/s40121-018-0214-1		49	
Position in topic ③	Efficacy and Safety of Meropenem-Vaborbactam Versus Best Available Therapy for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Patients Without Prior Antimicrobial Failure: A Post Hoc Analysis.	https://link.springer.com/article/10.1007/s12325-019-00981-y		50	
Position in topic ④	Clinical Outcomes of Patient Subgroups in the TANGO II Study.	https://link.springer.com/article/10.1007/s40121-021-00405-x		51	
In Vitro Microbiology and Pharmacology Studies					
Position in topic ①	Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant Enterobacteriales Strains, Including Carbapenem-Resistant Isolates.	https://journals.asm.org/doi/full/10.1128/spectrum.04507-22?rfr_dat=cr_pub+		52	
Position in topic ②	Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints.	https://journals.asm.org/doi/full/10.1128/aac.02130-21?rfr_dat=cr_pub++0pub		53	
Position in topic ③	Meropenem-vaborbactam activity against carbapenem-resistant Enterobacteriales isolates collected in U.S. hospitals	https://journals.asm.org/doi/full/10.1128/aac.01951-19?rfr_dat=cr_pub++0pub		54	

Educational Activities Medical & Research Grants **Publications** Reference Labs & Susceptibility Testing Clinical Trials

Search Publications [Browse Publications](#)

VABOMERE [VIEW](#)

[Manuscripts](#) [Presentations](#)

Registrational and Pivotal Trial Data

Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.
JAMA. 2018;319(8):788-799.

Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.
Infect Dis Ther. 2018;7(4):439-455.

Efficacy and Safety of Meropenem-Vaborbactam Versus Best Available Therapy for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Patients Without Prior Antimicrobial Failure: A Post Hoc Analysis.
Adv Ther. 2019;36(7):1771-1777.

[Clinical Outcomes of Patient Subgroups in the TANGO II Study](#)

Educational Activities Medical & Research Grants **Publications** Reference Labs & Susceptibility Testing Clinical Trials

Search Publications [Browse Publications](#)

VABOMERE [VIEW](#)

[Manuscripts](#) [Presentations](#)

IDWeek 2017

Meropenem-Vaborbactam (VABOMERE) vs. Piperacillin-Tazobactam in TANGO I (A Phase 3, Randomized, Double-Blind Trial): Outcomes by Baseline MIC in Adults with cUTI or AP. Poster 1866

ASM Microbe 2017

Clinical Outcomes with Meropenem-Vaborbactam (M-V) by Extended-Spectrum B-Lactamase (ESBL) Production in TANGO 1, a Phase 3 Randomized Trial vs Piperacillin-Tazobactam (P-T). Poster 305

Meropenem-Vaborbactam (M-V): Clinical Outcomes by Bacteremia Status in Phase 3 Randomized, Double-Blind Trial in cUTIs (TANGO I). Poster 304

REZZAYO [VIEW](#)

Publications / Browse Manuscript Topics

Add/Edit Manuscript topics and manage the display order of topics

Publications Browse Subcategories

Add New Subcategory+

Click IN the cell to edit.



Active is not immediate - you have to Save to

Manuscript

Presentation

Search:

Position	Label	Actions
1		
2	Registrational and Pivotal Trial Data	
3	In Vitro Microbiology and Pharmacology Studies	
4	Review Articles	
5	Real-World Studies and Analyses	

Copy CSV

Showing 1 to 5 of 5 entries

Educational Activities Medical & Research Grants Publications Reference Labs & Susceptibility Testing Clinical Trials

Search Publications Browse Publications

VABOMERE

VIEW

Manuscripts Presentations

Registrational and Pivotal Trial Data

Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial. *JAMA*. 2018;319(8):788-799.

Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial. *Infect Dis Ther*. 2018;7(4):439-455.

Efficacy and Safety of Meropenem-Vaborbactam Versus Best Available Therapy for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Patients Without Prior Antimicrobial Failure: A Post Hoc Analysis. *Adv Ther*. 2019;36(7):1771-1777.

Clinical Outcomes of Patient Subgroups in the TANGO II Study.

Publications / Browse Presentation Meetings

Add/Edit Presentation meetings and manage the display order of meetings

Publications Browse Subcategories

Home / Publications Browse Subcategories

[Add New Subcategory+](#)

Click IN the cell to edit.
Active is not immediate - you have to [Save](#) for it to take effect

Manuscript **Presentation**

Search:

Position	Label	Actions
1	ECCMID 2024	
2	IDWeek 2023	
3	MAD-ID 2023	
4	ECCMID 2023	
5	IDWeek 2022	
6	ECCMID 2021	
7	IDWeek 2021	
8	IDWeek 2020	
9	IDWeek 2017	
10	ASM Microbe 2017	
11	IDWeek 2019	

Educational Activities Medical & Research Grants **Publications** Reference Labs & Susceptibility Testing Clinical Trials

[Search Publications](#) [Browse Publications](#)

VABOMERE

[VIEW](#)

Manuscripts **Presentations**

IDWeek 2017
Meropenem-Vaboractam (VABOMERE) vs. Piperacillin-Tazobactam in TANGO I (A Phase 3, Randomized, Double-Blind Trial): Outcomes by Baseline MIC in Adults with cUTI or AP. Poster 1866

ASM Microbe 2017
Clinical Outcomes with Meropenem-Vaboractam (M-V) by Extended-Spectrum B-Lactamase (ESBL) Production in TANGO 1, a Phase 3 Randomized Trial vs Piperacillin-Tazobactam (P-T). Poster 305

Meropenem-Vaboractam (M-V): Clinical Outcomes by Bacteremia Status in Phase 3 Randomized, Double-Blind Trial in cUTIs (TANGO I). Poster 304

REZZAYO

[VIEW](#)

KIMYRSA and ORBACTIV

[VIEW](#)

Ref Labs & Testing Documents

Manage the order and copy on Reference Labs & Susceptibility
Testing webpage

Reference Lab and Testing Document Labels

Home / Reference Lab and Testing Document Labels

Add New Label +

Change the order the docs appear in the box

*
Click IN the cell to edit.
Active is not immediate - you have to **Save** for it to take effect.

Search:

Sort Order	ID	Name	Default Label *	Is Active *
1	1	AST	Antimicrobial Susceptibility Testing (AST)	<input checked="" type="checkbox"/>
2	2	RLT	Reference Lab Testing	<input checked="" type="checkbox"/>
3	3	RVV	Resources for Validation-Verification	<input checked="" type="checkbox"/>
4	8	ZZZ	New Label	<input type="checkbox"/>
5	10	xxx		<input type="checkbox"/>

Change the copy that appears in the box

Previous 1 Next

Save Cancel

Reference Labs & Susceptibility Testing Clinical Trials

infective drugs should be used only to treat or prevent infections that are proven or strongly
g or modifying antibacterial therapy. In the absence of such data, local epidemiology and
methods and quality control standards recognized by FDA, please see:

**REZZAYO®
(rezafungin for injection)**
[Antimicrobial Susceptibility Testing \(AST\)](#)
[Reference Lab Testing](#)
[Resources for Validation-Verification](#)

**ORBACTIV®
(oritavacin) for injection**
[Antimicrobial Susceptibility Testing \(AST\)](#)

**BAXDELA®
(delafloxacin)**
[Antimicrobial Susceptibility Testing \(AST\)](#)

[Resources for Validation-Verification](#)

Medical Information Requests

Medical Information Requests

[Home](#) / Medical Information Requests

Show entries

Search:

View	InquiryID	Req Date	Product	Company	Request	HCP Name/Contact	Speak to MSD	Stage
	77700036	8/12/24	Kimyrsa	ASCENSION SAINT FRANCIS HOSPITAL 355 RIDGE AVEUS	Hello, do you have any information regarding giving Kimyrsa 1200mg every 11 days for any...	MOHMED CHOTTI MOHMED.CHOTTI@ASCENSION.ORG 847-316-7719	NO	3:sent-to-sftp
	77700035	7/25/24	Kimyrsa	McKesson The Woodlands TX 77380 US	In the wake of Hurricane Beryl, product stability outside of the recommendations in the package...	Tim Ho tim.ho@mckesson.com 3094539060	NO	3:sent-to-sftp
	77700034	7/23/24	Rezzayo	Ascension St. Francis Hospital 3237 S 16th StreetUS	Hi Erica, My name is Kim Zittel, and I am the pharmaceutical buyer at Ascension...	Kim Zittel kim.zittel@ascension.org 4146475043	YES Erica Fernandez	3:sent-to-sftp
	77700033	7/2/24	Kimyrsa	Shannon Medical Center 120 E HarrisUS	We are evaluating the use of Oritavancin in a patient requiring peritoneal dialysis. Are you...	Shay Neal shayneal@shannonhealth.org 325-747-5075	NO	3:sent-to-sftp

Showing 1 to 4 of 4 entries

Previous **1** Next

Users

Medical Science Directors

User's with Field Medical Role

MSD List

Medical Science Directors [Home](#) / [Medical Science Director](#)

[Add +](#)

Show entries Search:

Name	Title	Email	Phone	States	Territory	Territory Id	Photo	Active	Actions
Besu Teshome, PharmD, MSc, BCPS	Medical Science Director	bteshome@melinta.com	(512) 228-1208	Arkansas, Louisiana, Mississippi, Missouri, Tennessee	South Central Ozarks	897784			
Christina Andrzejewski, PharmD, BCIDP	Medical Science Director	candrzejewski@melinta.com	(908) 968-1300	Delaware, District of Columbia, Maryland, North Carolina, Ohio, Pennsylvania, Virginia, West Virginia	Atlantic Capital				
Erica Fernandez, PharmD, BCCCP, BCPS	Medical Science Director	efernandez@melinta.com	(312) 219-3032	Illinois, Indiana, Iowa, Kentucky, Michigan, Minnesota, Missouri, Nebraska, North Dakota, South Dakota, Wisconsin	Midwest, North Central Ozarks				
Marianna Fedorenko, PharmD, BCPS, BCIDP	Medical Science Director	mfedorenko@melinta.com	(201) 394-3552	New Jersey, New York	NYC Metro, NJ	110564			
Michael North, PharmD, BCPS	Medical Science Director	mnorth@melinta.com	(303) 913-8961	Arizona, California, Colorado, Hawaii, Idaho, Kansas, Missouri, Montana, Nebraska, Nevada, New Mexico, Oregon, Utah, Washington, Wyoming	West	897748			
Nicholas J Rufa,	Super Field Medical	nrufa@melinta.com	(914) 215-3434	California, New York, North Dakota, South Dakota	XYZ	987654			
Ronak Gandhi, PharmD	Medical Science Director	rgandhi@melinta.com	(781) 799-4372	Connecticut, Maine, Massachusetts, New Hampshire, New York, Rhode Island	New England & Upstate NY	897725			
Saagar Akundi, BCPS, BCMAS	Medical Science Director	sakundi@melinta.com	(512) 507-7816	New Mexico, Oklahoma, Texas	South Central	110566			
Sandy Estrada, PharmD, BCPS	Senior Medical Science Director	sestrada@melinta.com	(239) 233-9380	Alabama, Florida, Georgia, Puerto Rico, South Carolina	South Sunbelt	897741			

Edit MSD

Medical Science Directors

[Home](#) / Medical Science Directors

Edit

User Id: 163 MSD Id: 13

To modify user data (i.e. name, email, department and photo) click here [Edit User Record](#)

User

Nicholas J Rufa,

Title

Super Field Medical

States

- | | | | |
|--|--|---|--|
| <input type="checkbox"/> Alabama | <input type="checkbox"/> Illinois | <input type="checkbox"/> Nevada | <input checked="" type="checkbox"/> South Dakota |
| <input type="checkbox"/> Alaska | <input type="checkbox"/> Indiana | <input type="checkbox"/> New Hampshire | <input type="checkbox"/> Tennessee |
| <input type="checkbox"/> American Samoa | <input type="checkbox"/> Iowa | <input type="checkbox"/> New Jersey | <input type="checkbox"/> Texas |
| <input type="checkbox"/> Arizona | <input type="checkbox"/> Kansas | <input type="checkbox"/> New Mexico | <input type="checkbox"/> Trust Territories |
| <input type="checkbox"/> Arkansas | <input type="checkbox"/> Kentucky | <input checked="" type="checkbox"/> New York | <input type="checkbox"/> Utah |
| <input checked="" type="checkbox"/> California | <input type="checkbox"/> Louisiana | <input type="checkbox"/> North Carolina | <input type="checkbox"/> Vermont |
| <input type="checkbox"/> Colorado | <input type="checkbox"/> Maine | <input checked="" type="checkbox"/> North Dakota | <input type="checkbox"/> Virgin Islands |
| <input type="checkbox"/> Connecticut | <input type="checkbox"/> Maryland | <input type="checkbox"/> Northern Mariana Islands | <input type="checkbox"/> Virginia |
| <input type="checkbox"/> Delaware | <input type="checkbox"/> Massachusetts | <input type="checkbox"/> Ohio | <input type="checkbox"/> Washington |
| <input type="checkbox"/> District of Columbia | <input type="checkbox"/> Michigan | <input type="checkbox"/> Oklahoma | <input type="checkbox"/> West Virginia |
| <input type="checkbox"/> Florida | <input type="checkbox"/> Minnesota | <input type="checkbox"/> Oregon | <input type="checkbox"/> Wisconsin |
| <input type="checkbox"/> Georgia | <input type="checkbox"/> Mississippi | <input type="checkbox"/> Pennsylvania | <input type="checkbox"/> Wyoming |
| <input type="checkbox"/> Guam | <input type="checkbox"/> Missouri | <input type="checkbox"/> Puerto Rico | |
| <input type="checkbox"/> Hawaii | <input type="checkbox"/> Montana | <input type="checkbox"/> Rhode Island | |
| <input type="checkbox"/> Idaho | <input type="checkbox"/> Nebraska | <input type="checkbox"/> South Carolina | |

Territory Id

987654

Territory

XYZ

Therapeutic Area

isActive

Yes No

Save

Cancel

Users (Melinta)

User List

Users													
Add +													
Show <input type="text" value="25"/> entries												Search: <input type="text"/>	
Title	First	MI	Last	Suffix	Email	Phone	Roles	Departments	Photo	Active	Actions		
	Nicholas		Rufa		nick@cmeunited.com		Super Admin	Operations, Developer,					
	Nancy		Robasco		nancy@cmeunited.com		Super Admin	Field Medical, Developer,					
	Besu		Teshome		bteshome@melinta.com	(512) 228-1208	Employee	Field Medical,	/images/bteshome.png				
	Christina		Andrzejewski		candrzejewski@melinta.com	(908) 968-1300	Employee	Field Medical,	/images/candrzejewski.png				
	Erica		Fernandez		efernandez@melinta.com	(312) 219-3032	Employee	Field Medical,	/images/efernandez.png				
	John		Meyer		jmeyer@melinta.com		Admin	Operations,					
	Jennifer		Sanfilippo		jsanfilippo@melinta.com	(908) 617-1316	Employee	Executive, Legal,					
	Kara		Vuong		kvuong@melinta.com	(732) 762-3921	Admin	Medical Information,					
	Matthew	K	Balogh		mbalogh@melinta.com	(908) 617-1324	Super Admin	Operations,					
	Marianna		Fedorenko		mfedorenko@melinta.com	(201) 394-3552	Employee	Field Medical,	/images/mfedorenko.png				
	Michael		North		mnorth@melinta.com	(303) 913-8961	Employee	Field Medical,	/images/mnorth.png				
	Mark		Redell		mredell@melinta.com	(973) 307-7034	Employee	Executive,					
	Ashish		Bhatia		netrix02@melinta.com		Admin	Operations,					
	Nicholas	J	Rufa		nrufa@melinta.com	(914) 215-3434	Super	Field Medical,	/uploads/2024/08/sarah-minor-				

Edit User

Users Home / Users

Edit User ID: #3

Title

First
Nicholas

MI
J

Last
Rufa

Suffix

Credentials

Email
nrufa@melinta.com

Phone
914-215-3434

Pronouns

FAX

Roles
Super Admin

Department Field Medical [4]

- Select one
- Medical information
- Executive
- Legal
- Field Medical**
- Operations
- Developer

To modify MSD data (i.e. state, territory) click here [Edit MSD Record](#)

Address

City

State

ZIP

Country

Affiliation

Bio

Upload Image File 

Juploads/2024/08/sarah-minor-v2.jpg



Agree To Terms

IsActive
 Yes No

[Save](#) [Cancel](#)

Guests

Guests are users who registered on the public site for access to Publications/MIL documents or submitting a MIRF.

Guest List

Visitors

[Add +](#)

Show entries

Title	First	MI	Last	Suffix	Email	Phone	Roles	Departments	Photo	Date Created	Active	Actions
	Nicholas	J	Rufa		nrufa@melinta.com	(914) 215-3434	Visitor	Operations		8/28/23 11:15 AM ET		
	Joe		Jordan		jjordan1@iuhealth.org		Visitor			7/8/24 2:45 PM ET		
	Maria		Giannakos		maria.giannakos@optioncare.com		Visitor			7/8/24 7:18 PM ET		
	andrew		ferri		anf9114@nyp.org		Visitor			7/23/24 10:05 PM ET		
	Tim		Ho		tim.ho@mckesson.com		Visitor			7/25/24 2:35 PM ET		

Showing 1 to 5 of 5 entries

Edit Guest

Visitors [Home](#) / [Visitors](#)

Edit Visitor DB Id: 8

Title

First

MI

Last

Suffix

Pronouns

Email

Phone

FAX

Roles
Select one or more
 Super Admin
 Admin
 Employee
 Report
 Visitor

Department
Select one or more
 Medical Information
 Executive
 Legal
 Field Medical
 Operations
 Developer

Address

Media

mediaManager

[Home](#) / mediaManager

Directory: **assets/images** uploads

Upload: **Image** Doc Audio Video

Filter:



 Total JPG Files:18



/assets/images/hero-contactus-v6-a.jpg



/assets/images/contact-1.jpg



/assets/images/hero-contactus-v6-b.jpg



/assets/images/contactus-report.jpg



/assets/images/contact-1 2.jpg



/assets/images/contactus-call.jpg



/assets/images/hero-contactus-v6.jpg



/assets/images/connect-with-melinta.jpg



/assets/images/hero-subpage-bg.jpg



/assets/images/hero-subpage-bg.jpg